1887

Abstract

SUMMARY

The characterization of over 300 mutants, derived from two strains of poliovirus type 3 and selected for resistance to neutralization by monoclonal antibodies, has led to the further definition of the major antigenic site involved in neutralization. The site encompasses amino acids 89 to 100 of VP1. A subsidiary antigenic site near the C-terminus of VP1 has been identified for the Sabin vaccine strain of poliovirus type 3. Of 59 monoclonal antibodies to poliovirus type 3 examined, 27 had virus-neutralizing activity and 25 of these were identified as directed against the major site on VP1 (designated site 1), indicating the immunodominant role of this site. One of the six monoclonal antibodies that recognized the subsidiary antigenic site on VP1 (designated site 2) possessed virus-neutralizing activity. The identification of the principal antigenic site of the virus provides a rational basis for attempts at the development of synthetic oligopeptide vaccines against poliovirus type 3.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-66-5-1159
1985-05-01
2022-01-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/66/5/JV0660051159.html?itemId=/content/journal/jgv/10.1099/0022-1317-66-5-1159&mimeType=html&fmt=ahah

References

  1. Emini E. A., Kao S., Lewis A. J., Crainic R., Wimmer E. 1983; Functional basis of poliovirus neutralization determined with monospecific neutralising antibodies. Journal of Virology 46:466–474
    [Google Scholar]
  2. Evans D. M. A., Minor P. D., Schild G. C., Almond J. W. 1983; Critical role of an eight amino acid sequence of VP1 in neutralization of poliovirus type 3. Nature, London 304:459–462
    [Google Scholar]
  3. Ferguson M., Qi Yi-Hua., Minor P. D., Magrath D. I., Spitz M, Schild G. C. 1982; Monoclonal antibodies specific for the Sabin vaccine strain of poliovirus. Lancet ii:122–124
    [Google Scholar]
  4. Ferguson M., Minor P. D., Magrath D. L., Yi-Hua Qi, Spitz M., Schild G. C. 1984; Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies. Journal of General Virology 65:197–201
    [Google Scholar]
  5. Maccallum F. O. 1971; Hypogammaglobulinaemia in the United Kingdom. Medical Research Council Special Report Series No 310: pp 72–85
    [Google Scholar]
  6. Minor P. D., Schild G. C., Ferguson M., Mackay A., Magrath D. I., John A., Yates P. J., Spitz M. 1982; Genetic and antigenic variation in type 3 polioviruses: characterization of strains by monoclonal antibodies and T1 oligonucleotide mapping. Journal of General Virology 61:167–176
    [Google Scholar]
  7. Minor P. D., Schild G. C., Bootman J., Evans D. M. A., Ferguson M., Reeve P., Spitz M., Stanway G., Cann A. J., Hauptmann R., Clarke L. D., Mountford R. C., Almond J. W. 1983; Location and primary structure of a major antigenic site for poliovirus neutralization. Nature, London 301:674–678
    [Google Scholar]
  8. Racaniello V. R., Baltimore D. 1981; Cloned poliovirus complementary DNA in infections in mammalian cells. Science 214:916–919
    [Google Scholar]
  9. Shinnick T. M., Sutcliffe J. G., Green N., Lerner R. A. 1983; Synthetic peptide immunogens as vaccines. Annual Review of Microbiology 37:425–446
    [Google Scholar]
  10. Stanway G., Cann A. J., Hauptmann R., Hughes P., Clarke L. D., Mountford R. C., Minor P. D., Schild G. C., Almond J. W. 1983; The nucleic acid sequence of poliovirus type 3 Leon 12a1b: comparison with type 1. Nucleic Acids Research 11:5629–5643
    [Google Scholar]
  11. Stanway G., Hughes P. J., Mountford R. C., Reeve P., Minor P. D., Schild G. C., Almond J. W. 1984; Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon/12a1b. Proceedings of the National Academy of Sciences, U. S. A 81:1539–1543
    [Google Scholar]
  12. Wychowski C., Van Der Werf S., Siffert O., Crainic R., Bruneau P., Girard M. 1983; A poliovirus type 1 neutralization epitope is located within amino acid residues 93–104 or viral capsid polypeptide VP1. EMBO Journal 2:2019–2024
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-66-5-1159
Loading
/content/journal/jgv/10.1099/0022-1317-66-5-1159
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error